Market intelligence, pricing and access for pharma and biotech companies with decisions pending in Argentina, Mexico, Paraguay, Uruguay and Chile. Each deliverable answers a defined question, with verified local evidence and a recommendation, at a timing and a price agreed in advance.
Packages
Quarterly report on reimbursement, centralized purchasing, prices and regulation for high-cost drugs in Argentina, with implications for the subscriber's portfolio.
From USD 1,500 per quarter
See the package →One defined market, access or pricing question, answered in 10 business days with local evidence and a recommendation.
From USD 6,000
See the package →The position and expected decisions of payers, physicians and regulators in one country regarding a product or a disease area, gathered through anonymous in-depth interviews, in about four weeks.
From USD 9,000
See the package →Opportunity assessment, business case, or access and pricing strategy, with a closed scope, in 6 to 8 weeks.
From USD 20,000
See the package →For needs that do not fit these packages, Kovaris prepares custom proposals.
Why Kovaris
Import records, public tenders, reimbursement data and list prices, consolidated and cross-checked, complemented by interviews with the people who decide coverage, prescribing and registration.
Kovaris uses AI-assisted analysis tools to process sources, which makes delivery in days possible. Every data point is checked against its original source and every deliverable includes a methodology note.
Each deliverable presents scenarios with explicit assumptions and closes with a recommendation the team can stand behind in front of regional management or the company it represents.
Recent experience
Paraguay · 2026
A biotech company with a regional footprint needed to define its market entry routes and map the relevant stakeholders. Kovaris reviewed the coverage and purchasing routes for specialty products, the genetics, hemato-oncology and oncology centers, and the opinion leaders in each area. On that basis, the company set its entry plan and its first contacts.
Uruguay · 2025
A pharmaceutical company was assessing the entry of products from a manufacturing plant in India, across several therapeutic areas, and needed to set priorities. The areas were ranked by number of patients and feasibility of coverage by the Fondo Nacional de Recursos, the competition was analyzed and the registration requirements for each product were reviewed. The result was a prioritized list of molecules and a clear view of the requirements for entering the Uruguayan market.
Argentina · 2026 · Kovaris research
A reconstruction, from public sources, of how the price of icatibant moved when a second brand entered and then left the market, and of what the case shows about how a high-cost treatment is purchased and its price defended in Argentina. Published as a white paper in October 2026.
An initial 30-minute call is used to set out the question and the scope; the proposal, with the price and the delivery date, follows in writing.